Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia.
Frost BM, Nygren P, Gustafsson G, Forestier E, Jonsson OG, Kanerva J, Nygaard R, Schmiegelow K, Larsson R, Lönnerholm G; Nordic Society for Paediatric Haematology and Oncology. Frost BM, et al. Among authors: jonsson og. Br J Haematol. 2003 Aug;122(3):376-85. doi: 10.1046/j.1365-2141.2003.04442.x. Br J Haematol. 2003. PMID: 12877664 Free article.
In vitro cellular drug resistance adds prognostic information to other known risk-factors in childhood acute lymphoblastic leukemia.
Lönnerholm G, Thörn I, Sundström C, Frost BM, Flaegstad T, Heyman M, Jonsson OG, Harila-Saari A, Madsen HO, Porwit A, Schmiegelow K, Söderhäll S, Wesenberg F, Vettenranta K, Larsson R, Forestier E. Lönnerholm G, et al. Among authors: jonsson og. Leuk Res. 2011 Apr;35(4):472-8. doi: 10.1016/j.leukres.2010.09.001. Epub 2010 Oct 18. Leuk Res. 2011. PMID: 20961616
Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia.
Staffas A, Kanduri M, Hovland R, Rosenquist R, Ommen HB, Abrahamsson J, Forestier E, Jahnukainen K, Jónsson ÓG, Zeller B, Palle J, Lönnerholm G, Hasle H, Palmqvist L, Ehrencrona H; Nordic Society of Pediatric Hematology and Oncology (NOPHO). Staffas A, et al. Among authors: jonsson og. Blood. 2011 Nov 24;118(22):5905-13. doi: 10.1182/blood-2011-05-353185. Epub 2011 Oct 3. Blood. 2011. PMID: 21967978 Free article.
Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004.
Hasle H, Abrahamsson J, Forestier E, Ha SY, Heldrup J, Jahnukainen K, Jónsson ÓG, Lausen B, Palle J, Zeller B; Nordic Society of Paediatric Haematology and Oncology (NOPHO). Hasle H, et al. Among authors: jonsson og. Blood. 2012 Aug 2;120(5):978-84. doi: 10.1182/blood-2012-03-416701. Epub 2012 Jun 22. Blood. 2012. PMID: 22730539 Free article. Clinical Trial.
Outcome of poor response paediatric AML using early SCT.
Wareham NE, Heilmann C, Abrahamsson J, Forestier E, Gustafsson B, Ha SY, Heldrup J, Jahnukainen K, Jónsson ÓG, Lausen B, Palle J, Zeller B, Hasle H. Wareham NE, et al. Among authors: jonsson og. Eur J Haematol. 2013 Mar;90(3):187-94. doi: 10.1111/ejh.12051. Epub 2013 Jan 20. Eur J Haematol. 2013. PMID: 23215948
Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol.
Toft N, Birgens H, Abrahamsson J, Bernell P, Griškevičius L, Hallböök H, Heyman M, Holm MS, Hulegårdh E, Klausen TW, Marquart HV, Jónsson OG, Nielsen OJ, Quist-Paulsen P, Taskinen M, Vaitkeviciene G, Vettenranta K, Åsberg A, Schmiegelow K. Toft N, et al. Among authors: jonsson og. Eur J Haematol. 2013 May;90(5):404-12. doi: 10.1111/ejh.12097. Epub 2013 Apr 2. Eur J Haematol. 2013. PMID: 23461707
114 results